

Docket No. 239637US8


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Thomas NILSSON, et al.

SERIAL NO: 10/603,818

FILED: June 26, 2003

FOR: COMBINED DOSES



GAU: 1616

EXAMINER: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449 which were cited in an International Search Report for International Application No. PCT/SE2004/000953. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

A handwritten signature in black ink, appearing to read "Bradley D. Lytle".

Bradley D. Lytle

Registration No. 40,073

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



SHEET OF

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
239637US8SERIAL NO.
10/603,818

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Thomas NILSSON, et al.

FILING DATE

June 26, 2003

GROUP

1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,901,883	5-11-99	RITSCHÉ			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	WO 03/061743	7-31-03	WIPO	x	
	AP	WO 03/077825	9-25-03	WIPO	x	
	AQ	WO 02/11711	2-14-02	WIPO	x	
	AR	WO 01/76601	10-18-01	WIPO	x	
	AS	WO 00/64520	11-2-00	WIPO	x	
	AT	EP 1300171	4-9-03	European	x	
	AU	WO 02/085281	10-31-02	WIPO	x	
	AV	WO 00/64519	11-2-00	WIPO	x	
	AW	WO 01/78737	10-25-01	WIPO	x	
	AX	WO 02/24268	3-28-02	WIPO	x	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AY	Pediatric Pulmonology, Vol. 30, 2000, N.J. Van den Berg et al, "Salmeterol/Fluticasone Propionate (50/100 ug) in Combination in a Diskus TM Inhaler (Seretide TM) Is Effective and Safe in Children With Asthma", pages 97-105				
	AZ	European Respiratory Journal, Vol. 2, suppl. 28, 1998, M. Ringdal et al, "Asthma control with salmeterol and fluticasone propionate (50/250 u.g) Given twice daily in a single combination diskus (accuhaler) inhaler compared to salmeterol, 50 ug and fluticasone propionate 250 ug given twice daily via two separate diskus inhalers", page 36s, column P0330				
	BA	European Respiratory Journal, Vol 12, suppl. 28, 1998, N.J. van den Berg et al, "Combined salmeterol xinafoate and fluticasone propionate (50/100 ug strength) BD via one diskus (accuhaler) inhaler compared with salmeterol xinafoate 50 ug and fluticasone propionate 100 ug BD via two separate diskus inhalers", page 157s, column P1108				
	BB	"Delivery of Ipratropium and Albuterol Combination Therapy for Chronic Obstructive Pulmonary Disease: Effectiveness of a Two-in-one Inhaler Versus Separate Inhalers", The American Journal of Managed Care, Vol. 8, October 2002, Elizabeth Chrischilles et al, pages 902-911.			<input type="checkbox"/> Additional References sheet(s) attached	

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.